智飞生物(300122.SZ)发布前三季度业绩，归母净亏损12.06亿元

Core Insights - The company reported a significant decline in revenue for the first three quarters of 2025, with total revenue amounting to 7.627 billion yuan, representing a year-on-year decrease of 66.53% [1] - The net loss attributable to shareholders of the listed company reached 1.206 billion yuan, indicating financial challenges [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 1.227 billion yuan, highlighting ongoing operational difficulties [1] - The basic loss per share was reported at 0.504 yuan, reflecting the company's struggles in maintaining profitability [1]